Literature DB >> 10190919

Serologic testing for inflammatory bowel disease.

E J Hoffenberg1, S Fidanza, A Sauaia.   

Abstract

OBJECTIVES: To determine the accuracy of anti-neutrophil cytoplasmic antibodies (ANCAs) and anti-Saccharomyces cerevisiae antibodies (ASCA) in distinguishing patients with inflammatory bowel disease from patients with other disorders, seen in a pediatric gastroenterology clinic setting, and in distinguishing ulcerative colitis (UC) from Crohn's disease (CD). STUDY
DESIGN: Serum samples from 120 children with new or established diagnoses of UC (n = 25) or CD (n = 20) and control children (n = 74) were analyzed in blinded fashion for the presence of IgG ANCAs and IgA and IgG ASCA.
RESULTS: The highest sensitivity for detecting inflammatory bowel disease, 71%, was achieved by using ANCAs and ASCA together. The best test for UC was ANCAs, which had a sensitivity of 80%. However, the ANCA pattern characteristic of UC, perinuclear ANCAs eliminated by DNAse, had a sensitivity of 60%. High-titer ANCAs were specific for UC, whereas ASCA were specific for CD.
CONCLUSIONS: Testing for ANCAs and ASCA together did not achieve sensitivity necessary for population screening. However, ANCAs and ASCA may be helpful in evaluating children suspected of having inflammatory bowel disease and in distinguishing UC from CD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10190919     DOI: 10.1016/s0022-3476(99)70202-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

Review 1.  Inflammatory bowel disease.

Authors:  R M Beattie; N M Croft; J M Fell; N A Afzal; R B Heuschkel
Journal:  Arch Dis Child       Date:  2006-05       Impact factor: 3.791

2.  Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy.

Authors:  I E A Hoffman; P Demetter; M Peeters; M De Vos; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

3.  Utility of fecal and serum anti-Saccharomyces cerevisiae antibodies in the diagnosis of Crohn's disease-like condition of the pouch.

Authors:  Linda Y Tang; Hui Cai; Udayakumar Navaneethan; James H Boone; Sarah J Rhodes; Lauren Moore; Hyunjin Rho; Carol de La Motte; Elaine Queener; Bo Shen
Journal:  Int J Colorectal Dis       Date:  2012-03-20       Impact factor: 2.571

4.  Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.

Authors:  Marla Cindy Dubinsky
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

5.  Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease.

Authors:  E Israeli; I Grotto; B Gilburd; R D Balicer; E Goldin; A Wiik; Y Shoenfeld
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 6.  Immunogenetic phenotypes in inflammatory bowel disease.

Authors:  Marla-C Dubinsky; Kent Taylor; Stephan-R Targan; Jerome-I Rotter
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

7.  Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease.

Authors:  Jan G M C Damoiseaux; Bas Bouten; Annick M L W Linders; Jos Austen; Caroline Roozendaal; Maurice G V M Russel; Pierre-Philippe Forget; Jan Willem Cohen Tervaert
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

8.  Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease.

Authors:  D G Forcione; M J Rosen; J B Kisiel; B E Sands
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 9.  Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.

Authors:  Marla Dubinsky; Jonathan Braun
Journal:  Gastroenterology       Date:  2015-08-15       Impact factor: 22.682

10.  Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease.

Authors:  Zsolt Barta; István Csípõ; Gábor G Szabó; Gyula Szegedi
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.